Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher
Source: SeekingAlpha
2025-12-15 17:44:12 ET
Introduction
Milestone Pharmaceuticals Inc. ( MIST ) news reached my desk last week with the FDA approval of its nasal spray, CARDAMYST , which is described as a...
Read the full article on Seeking Alpha
For further details see:
Milestone Pharmaceuticals: Cardamyst Beat Placebo, But The Commercial Bar Is Higher
Milestone Pharmaceuticals Inc.
NASDAQ: MIST
MIST Trading
1.16% G/L:
$1.745 Last:
672,931 Volume:
$1.77 Open:
MIST Latest News
February 26, 2026 08:00:00 am
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
February 10, 2026 08:00:00 am
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
MIST Stock Data
$157,137,440
68,561,322
0.37%
48
N/A
Biotechnology & Life Sciences
Healthcare
CA
Montral
